{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Epimedii Folium", "molecular docking", "network pharmacology", "osteoporosis"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31872744", "DateCompleted": {"Year": "2020", "Month": "01", "Day": "13"}, "DateRevised": {"Year": "2020", "Month": "01", "Day": "13"}, "Article": {"ArticleDate": [], "Language": ["chi"], "ELocationID": ["10.19540/j.cnki.cjcmm.20190325.401"], "Journal": {"ISSN": "1001-5302", "JournalIssue": {"Volume": "44", "Issue": "18", "PubDate": {"Year": "2019", "Month": "Sep"}}, "Title": "Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica", "ISOAbbreviation": "Zhongguo Zhong Yao Za Zhi"}, "ArticleTitle": "[Molecular mechanism of Epimedii Folium in treatment of osteoporosis based on network pharmacology].", "Pagination": {"StartPage": "4048", "EndPage": "4052", "MedlinePgn": "4048-4052"}, "Abstract": {"AbstractText": ["Osteoporosis is a systematic bone disease,characterized by deterioration in bone mass or micro-architecture,and increasing risk of fragility and fractures. With the development of aging problems,osteoporosis has been a global health problem. At present,due to the undesirable side effects of synthetic osteoporosis inhibitors,more efforts are made in treatment of osteoporosis by traditional Chinese medicine and its prescriptions. Epimedii Folium,one of the most common herbs for osteoporosis,has attracted great attentions worldwide.In this study,network pharmacology was employed to analyze the active components and potential molecular mechanism of Epimedii Folium on osteoporosis. Component-target network analysis showed that those with higher molecular network degree were flavonoids,with estrogen-like activity,antioxidation and free radical-scavenging activities,playing certain roles in preventing and treating osteoporosis. On the other hand,the targets with high degree were mostly related with sex hormone,osteoclast differentiation,bone matrix degradation,and reactive oxygen species in drug-target network. Multiple components of Epimedii Folium could be interacted with these targets. This study shows that Epimedium could prevent and treat osteoporosis through multiple active ingredients acting on multiple targets."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Jiangsu Kanion Pharmaceutical Co.,Ltd. Lianyungang 222001,China State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process Lianyungang 222001,China."}], "LastName": "Ke", "ForeName": "Zhi-Peng", "Initials": "ZP"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Jiangsu Kanion Pharmaceutical Co.,Ltd. Lianyungang 222001,China State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process Lianyungang 222001,China."}], "LastName": "Zhang", "ForeName": "Xin-Zhuang", "Initials": "XZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Jiangsu Kanion Pharmaceutical Co.,Ltd. Lianyungang 222001,China State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process Lianyungang 222001,China."}], "LastName": "Cao", "ForeName": "Ze-Yu", "Initials": "ZY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Jiangsu Kanion Pharmaceutical Co.,Ltd. Lianyungang 222001,China State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process Lianyungang 222001,China."}], "LastName": "Cao", "ForeName": "Liang", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Jiangsu Kanion Pharmaceutical Co.,Ltd. Lianyungang 222001,China State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process Lianyungang 222001,China."}], "LastName": "Wang", "ForeName": "Zhen-Zhong", "Initials": "ZZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Jiangsu Kanion Pharmaceutical Co.,Ltd. Lianyungang 222001,China State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process Lianyungang 222001,China."}], "LastName": "Xiao", "ForeName": "Wei", "Initials": "W"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "China", "MedlineTA": "Zhongguo Zhong Yao Za Zhi", "NlmUniqueID": "8913656", "ISSNLinking": "1001-5302"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Drugs, Chinese Herbal"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Drugs, Chinese Herbal"}, {"QualifierName": ["chemistry"], "DescriptorName": "Epimedium"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Medicine, Chinese Traditional"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Osteoporosis"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plant Leaves"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2019", "Month": "12", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "12", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "14", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31872744", "10.19540/j.cnki.cjcmm.20190325.401"]}}]}